J Pediatric Infect Dis Soc
. 2021 Jul 28;piab060.
doi: 10.1093/jpids/piab060. Online ahead of print.
Perimyocarditis in Adolescents After Pfizer-BioNTech COVID-19 Vaccine
Eric Tano 1 , Stephanie San Martin 1 , Stephen Girgis 1 , Yadira Martinez-Fernandez 2 , Carolina Sanchez Vegas 3
Affiliations
- PMID: 34319393
- DOI: 10.1093/jpids/piab060
Abstract
On May 10, 2021, the Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) was expanded to include adolescents (May 10, 2021. https://www.fda.gov/news-events/pres...-emergency-use). We describe clinical characteristics of 8 adolescents who presented over the course of 36 days to Nicklaus Children's Hospital with perimyocarditis within 4 days of receiving a dose of BNT162b2 vaccine.
Keywords: BNT162b2; COVID-19 vaccine; myocarditis; pericarditis.